AR and prostate small cell carcinoma: Initially described as a poorly differentiated adenocarcinoma, PC3 was further demonstrated to express typical features of prostatic small-cell neuroendocrine carcinoma including AR and PSA absence, neuroendocrine and CD44 marker expression, and androgen independency33,34.